miR-128 regulates the apoptosis and proliferation of glioma cells by targeting RhoE

CHAO SHANG¹, YANG HONG², YAN GUO³, YUN-HUI LIU² and YI-XUE XUE¹

¹Department of Neurobiology, College of Basic Medicine, China Medical University, Shenyang, Liaoning 110001; ²Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning 110004; ³Department of Central Laboratory, School of Stomatology, China Medical University, Shenyang, Liaoning, P.R. China

Received November 24, 2014; Accepted October 12, 2015
DOI: 10.3892/ol.2015.3927

Correspondence to: Professor Yi-Xue Xue, Department of Neurobiology, College of Basic Medicine, China Medical University, 92 Beier Road, Heping, Shenyang, Liaoning 110001, P.R. China. E-mail: xueyixue2012@163.com

Key words: glioma, miR-128, RhoE, U251 cell

Abstract. In this study, we investigate whether miR-128 is capable of regulating the apoptosis and proliferation of human U251 glioma cells by downregulating RhoE. The expression of miR-128 was assessed by quantitative polymerase chain reaction in normal brain tissue and glioma samples. A significant downregulation of the expression of miR-128 was detected in glioma in contrast to normal brain tissue. Following the transfection of pre-miR-128 and anti-miR-128 into U251 cells, the high expression of miR-128 could inhibit proliferation and induce apoptosis in U251 cells, and those effects could be restored by miR-128 knockdown. To analyze the regulation mechanism of miR-128, TargetScan, miRanda and PicTar were used to ascertain whether RhoE was a potential target gene. Next, luciferase activity assay and western blot analysis confirmed that RhoE was a direct and specific target gene of miR-128. The advanced effects of pre-miR-128 on the apoptosis and proliferation of U251 cells were reversed by the upregulation of RhoE expression. In summary, aberrantly expressed miR-128 regulates apoptosis and proliferation in human glioma U251 cells partly by directly targeting RhoE. This finding may offer a new potential therapeutic strategy for the treatment of glioma.

Introduction

Glioma is the most common primary tumor in the nervous system, and has the highest mortality rate among endocranial tumors due to its malignant proliferation and invasion characteristics (1). Gliomas are rarely curable. Treatment for glioma includes surgery, chemotherapy or radiation therapy, depending on the patient. Surgery is the most significant initial approach, and chemotherapy and radiotherapy following the initial surgical resection is effective in preventing recurrence and metastasis (2). However, chemotherapy is only effective for ~50% of individuals treated for glioma. For this reason, the prognosis remains poor, particularly for patients with high-grade glioma, even when prompt and comprehensive treatment is administered. The median survival time for adults with an anaplastic astrocytoma is 2-3 years, and for those with more aggressive glioblastomas, the median survival time drops off to 12-14.6 months, with a two-year median survival rate of 30% (3).

miR-128 is an anti-oncogene which is expressed at low levels in certain malignant tumors, including glioma (6,7). miR-128 specifically inhibits a number of target genes related to tumor cell characteristics, including apoptosis and proliferation (8,9). Evidence suggests that miR-128 is an apoptosis-induced factor and functions at least in part by targeting a host of apoptosis-related genes, including Bmi-1, EGFR and E2F3 (10). miR-128 may silence the expression of certain anti-apoptotic genes and induce apoptosis in cancer cells.

Our study identified that miR-128 was expressed at lower levels in glioma samples than in controls. Upregulation of miR-128 inhibited U251 cell proliferation by targeting the RhoE gene at the translational level. Our novel findings suggest that abnormal expression of miR-128 is pivotal for the apoptosis and proliferation of human glioma cells. Further related research may aid the development of new therapeutic strategies against glioma.

Materials and methods

Clinical specimens. A total of 48 glioma and corresponding paracancerous tissues were provided by the Department of Neurosurgery at Shengjing Hospital of China Medical University between November 2012 and April 2014. The study was approved by the hospital's ethics committees, and we obtained consent from all patients prior to surgery. All specimens were obtained from patients through surgical
resection and then histologically proven to be gliomas. None of the patients had undergone radiation or chemotherapy before surgery. Following surgery, the tissue samples were stored at -80˚C, and the pathological information was obtained shortly after.

**Quantitative polymerase chain reaction (qPCR).** After total RNA was extracted from tissue and cell samples, cDNA was synthesized and used to detect the mRNA expression with a miRNA detection kit (Invitrogen Life Technologies, Carlsbad, CA, USA) (11). The samples were normalized to 18S and the CT values from 18 to 30 were calculated by the 2^ΔΔCT method using the Applied Biosystems 7500 system (Applied Biosystems; Thermo Fisher Scientific, Waltham, MA, USA).

**Transfection.** Twenty-four hours before transfection, an appropriate concentration (~80%) of resuspended U251 cells were seeded on six-well plates. The miRNAs or expression vectors (Life Technologies, Grand Island, NY, USA) were transfected into U251 cells with Lipofectamine™ 2000 reagent (Invitrogen Life Technologies). The final concentration of miRNAs was 60 nM. The transfected cells were incubated for 4 h, and normal media were added. After 48 h, the cells were harvested for further studies.

**Flow cytometry detection.** Cells (5x10⁴) were harvested, and an apoptosis detection kit (Biosea, Beijing, China) was used to examine the apoptosis rate in accordance with the manufacturer's instructions. Next, the cells were read by flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA) (Ex, 488 nm; Em, 635 nm), and the obtained numerical values were analyzed with CellQuest 3.0 software (BD Biosciences). Annexin V-positive cells were considered as apoptotic cells. The cells were counted by a dual-color flow cytometric method.

**Cell proliferation assay.** Cells were seeded in a 96-well plate with 2x10⁴ cells per well. Twenty microliters of 0.5 mg/ml MTT solution (Sigma-Aldrich, St. Louis, MO, USA) was added to each well, and the 96-well plate was incubated at 37˚C. The media were replaced after 4 h, and 0.2 ml DMSO was added to each well. The 96-well plate was incubated for 30 min, and results were read on an enzyme-labeled instrument (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a 570 nm wavelength. The obtained numerical values were used to construct the cell growth curve.

**Target prediction.** The prediction of the RhoE 3′-untranslated region (UTR) as a miRNA binding target was determined using Targetscan (www.targetscan.org), miRanda (www.mirbase.org) and PicTar (pictar.mdc-berlin.de). miRNAs that were simultaneously predicted by all three programs were selected for this study.

**Vector construction and luciferase reporter assay.** The luciferase reporter vectors were constructed by Invitrogen Life Technologies. The RhoE 3′-UTR, which included miR-128 seed-binding sites, was cloned into the pGL3-promotor vector to construct the wide-type (WT) vector, and the predicted seed zone with miR-128 was replaced by nonsense sequences in the mutation-type (MuT) vector.

In the luciferase reporter assay, 100 ng RhoE 3′UTR luciferase construct and 400 ng microRNA were cotransfected into U251 cells, and the Dual-Glo luciferase assay (Promega Corporation, Madison, WI, USA) was applied to quantitate the relative luciferase activity, which was computed by the luciferase activity of firefly to renilla. In order to normalize the transfection efficiency, the β-galactosidase expression vector was used in every transfection.

**Western blot analysis.** Cells were harvested and protein was extracted. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and antibody hybridization were performed as described previously (12). The ECL analysis system (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used for detection in accordance with the manufacturer's instructions. Western blot quantification was performed using Fluor Chen 2.0 image processing and analysis software (Bio-Rad Laboratories, Inc.). GAPDH was selected as the reference protein.

**Statistical analysis.** All experiments were carried out three times. All numerical data were presented as the means ± standard deviation and analyzed with SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance was used to analyze the statistical significance. P<0.05 and P<0.001 were considered to indicate a statistically significant difference.

**Results**

**miR-128 is downregulated in glioma specimens.** In order to research the potential effect of miR-128 in glioma, the expression of miR-128 was firstly analyzed in 48 glioma and corresponding paracancerous tissue samples. Compared with the matching paracancerous tissues, miR-128 expression in glioma was notably decreased (P<0.001; Fig. 1). Furthermore, the expression of miR-128 was negatively correlated with the pathological grade of glioma (P<0.01; Table I).

**miR-128 functions as an anti-oncogene in glioma cells.** We investigated whether miR-128 influences apoptosis and proliferation using U251 cells. Pre-miR-128 was transfected into U251 cells to increase miR-128 expression (Fig. 2). In comparison with control U251 cells, the growth inhibitory rate of U251 cells with miR-128 overexpression was markedly increased by MTT assay (Fig. 3A). Flow cytometry revealed that the apoptosis rate of U251 cells with miR-128 overexpression was 7.83%, and that of control U251 cells was 3.18%. The statistical analysis revealed that the apoptosis rate increased significantly (Fig. 3C).

**RhoE is a direct and specific target of miR-128 in U251 cells.** We then investigated the mechanisms of how miR-128 affects the apoptosis and proliferation phenotype in U251 cells. An online search of the target genes of miR-128 by TargetScan, miRBase and PicTar indicated that RhoE gene was a possible target of miR-128 (Fig. 4A).

qPCR was used to confirm that the expression of the RhoE gene was upregulated significantly in glioma tissues compared with matching paracancerous tissues (Fig. 1).
Furthermore, Pearson’s correlation analysis revealed a negative correlation between the expression of miR-128 and RhoE. The luciferase reporter assay was performed to identify the direct miR128-RhoE interaction. Pre-miR-128 and various reporter vectors were cotransfected into U251 cells respectively. As shown in Fig. 4C, the relative luciferase activity was much lower in U251 cells cotransfected with WT vector and pre-miR-128 than in other transfected U251 cells. These results indicate that miR-128 could specifically bind to the seed zone of RhoE 3’UTR to inhibit its expression, while the MuT vector which changed the pivotal binding sequence could not be combined with miR-128 to decrease the relative luciferase activity. RhoE is a specific and direct target gene of miR-128.

Next, we confirmed the regulatory effects of miR-128 on endogenous RhoE expression. The results revealed that pre-miR-128 increased the miR-128 expression level efficiently, and anti-miR-128 demonstrated a contradictory regulative effect (Fig. 2). Western blot analysis revealed that the RhoE protein level was significant suppressed with miR-128 enhancement and was upregulated significantly in U251 cells transfected with anti-miR-128 (Fig. 4B and D), whereas the qPCR results demonstrated that endogenous RhoE expression was not significantly altered in U251 cells (data not shown). Together, these results confirm that miR-128 negatively regulates endogenous RhoE expression at the post-translational level.

RhoE expression mediates the effect of miR-128 on U251 cell apoptosis and proliferation. Given the fact that miR-128 regulated the apoptosis and proliferation of U251 cells, and RhoE was the target gene of miR-128, we studied the physiological role of miR-128-target RhoE in U251 cells following the upregulation of RhoE expression. As shown in Fig. 3B and D, the transfection of the RhoE expression vector significantly upregulated the protein expression of RhoE, which was expressed at low levels in U251 cells transfected with pre-miR-128.

After the expression of RhoE protein was upregulated, the growth inhibitory rate was markedly reduced (Fig. 3A), and the apoptosis rate of U251 cells decreased from 7.83 to 2.87%, which was statistically significant (Fig. 3C).

Combined with our substantial evidence that miR-128 inversely regulated RhoE expression, we confirm that miR-128-controlled apoptosis and proliferation of U251 cells is mediated to a large extent through RhoE downregulation.

Discussion

It is well known that glioma cells have significant proliferation ability and a low apoptosis rate, as well as a powerful resistance to chemotherapy, radiation and biological treatment (13-15). These characteristics contribute to the malignant growth of tumors and may be a key reason for the recurrence of glioma (16).
It is known that aberrant miRNA expression regulates critical biological behavior, including apoptosis and proliferation, which may promote glioma cell development and lead to a poor prognosis (17,18). Our study revealed that miR-128 was also expressed at low levels in brain glioma. Overexpression of miR-128 could increase the apoptosis rate of U251 cells and suppress proliferation. Thus, we suggest that the expression and functional changes of miR-128 are crucial in the genesis and development of glioma.

Since miRNAs exert their roles by targeting different genes, for example miR-10b and E-cadherin, and miR-320a and ITGB3 (19,10), we speculate that miR-128 regulated a single gene to modify the regulation network and trigger cell apoptosis and proliferation in U251 cells in our study. Computational algorithms are effective tools to predict and validate the miRNA gene targets. Through analysis using TargetScan, miRanda and PicTar, a number of key candidate targets for miR-128 were predicted. Among these potential targets, RhoE is the most significant.

RhoE, also known as RND3, belongs to the Ras superfamily and is a small Rho GTPase. It has been regarded as a significant effector of cell biological characteristics, including cell cycle, apoptosis and migration (20,21). RhoE was originally identified as an endogenous ROCK1 inhibitor, and binds...
to ROCK1 to inhibit downstream signaling (22). Previous studies have emphasized the critical role of RhoE in a number of cancer types. The expression of RhoE decreased in lung and hepatocellular carcinoma (21,23). However, RhoE is upregulated in certain cancers, included glioma (24). These differences suggest that Rnd3 has specific roles in different cell lineages.

Our results obtained from gain-of-function approaches confirmed that RhoE is a direct target gene of miR-128. Firstly, the RhoE gene was upregulated in glioma tissues, and its expression demonstrated a negative correlation with the expression of miR-128. Second, overexpression of miR-128 notably reduces the relative luciferase activity of the WT vector containing RhoE 3’UTR. Third, mutation at the miR-128 target site in the 3’UTR of RhoE significantly decreased the miR-128 regulation effect. Fourth, overexpression of miR-128 inhibits the expression of RhoE protein at the post-translational level, and knockdown of miR-128 demonstrated the opposite effect. In summary, we conclude that RhoE is a direct and pivotal target gene of miR-128.

Our studies have identified that transfection of the RhoE expression vector upregulated the expression of RhoE, which demonstrated a low expression in U251 cells transfected with pre-miR-128, and strongly influenced the apoptosis and proliferation of U251 cells. All of these results indicate that miR-128 inhibited RhoE protein expression, and the apoptosis and proliferation regulated by miR-128 may be reversed by the overexpression of RhoE. Accordingly, the verification of RhoE as a target gene of miR-128 offers a probable reason as to why the low expression of miR-128 functions as a tumor-suppressing gene in U251 cells. However, further ongoing research is essential to identify the detailed molecular mechanism of miR-128 in the genesis and development of glioma.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grants 81172408 and 81301862).

References